When Recessive Genes Mutate to Dominant Gene Action
ported [Hochstenbach et al., 2012] . Two recent publications challenge this relatively clear-cut picture and may even 'blur the borders of dominant and recessive inheritance' [Lemke et al., 2016; Vissing et al., 2016] .
In 37 patients of 10 independent pedigrees, a 21-bp inframe deletion (c.643_663del21) in the CAPN3 gene cosegregated with signs of muscle disease consistent with autosomal dominant transmission through several generations [Vissing et al., 2016] . The 36 patients who were available for thorough evaluation showed muscle pain, muscle weakness and wasting, fat replacement of muscle tissue, and myopathic changes in muscle biopsies. These phenotypes were generally milder than in patients with autsomal recessive limb girdle muscular dystrophy type 2A but affected the same muscles. The in-frame deletion causes a loss of 7 amino acid residues in the N-terminal calpain-like thiol protease domain of the calpain 3 protein. Western blotting of muscle protein extracts from 9 patients showed less than 15% calpain 3 protein remaining. This level of gene expression cannot be explained by invoking nonsense-mediated mRNA decay. More likely is that the allele with the intragenic deletion suppresses calpain 3 protein concentrations to a very low level, which amounts to dominant negative gene action [Veitia, 2010] .
The NMDA receptors are tetrameric ligand-gated ion channels permeable to Na, K, and Ca, which are composed of 2 glycine-binding GluN1 subunits and 2 glutaExamination of pedigrees reveals whether a trait or a disease phenotype is being transmitted in a recessive, dominant or X chromosome-linked mode. For a recessive disease, both alleles of a gene have to be mutated or entirely lost. This may come about if both healthy parents transmit a mutated allele or a loss, or if one transmitted, mutated allele is combined with a second allele that has undergone a de novo mutation or loss. The likelihood of both parents being healthy, heterozygous carriers of mutations depend on the population frequency of mutated alleles, which varies widely among genes. The rate of de novo single nucleotide variation (SNV) is estimated to be approximately 1.0-1.5 × 10 − 8 and the rate of de novo CNV 1.2 × 10 − 2 per meiosis [Itsara et al., 2010; Campbell and Eichler, 2013; Rahbari et al., 2016] . These rates depend upon the age of the father and the nucleotide distribution characteristics of the loci in question [Buizer-Voskamp et al., 2013; Francioli et al., 2015; Rahbari et al., 2016] . A few dozens of cases have been reported in which a transmitted or a de novo gene loss 'unmasks' a transmitted or a de novo SNV [Flipsen-ten Berg et al., 2007; Poot and Haaf, 2015] . Such 'unmasking' has been found more often in patients who exhibit phenotypes reminiscent of 2 syndromes occurring simultaneously than in patients with novel assortments of phenotypes [Hochstenbach et al., 2012; Poot and Haaf, 2015] . Of the latter, a case with 2 overlapping losses affecting a single gene has been re- In addition, heterozygous truncation of GRIN1 did not result in neurological phenotypes, and deletions encompassing GRIN1 as well as truncating or splice-site variants were also found in healthy individuals. This suggests that haploinsufficiency of GRIN1 is tolerated in the healthy human population. Conceivably, these 2 apparently disparate sets of observations can be subsumed under a single paradigm. The proteins encoded by the CAPN3 and GRIN1 genes have to form multimeric complexes by binding to proteins encoded by other genes. The level of multimer formation would be reduced by those mutations in CAPN3 and GRIN1 encoded proteins affecting the domain that binds the other protein. Multimers with such mutant proteins would either be completely inactive, 'leaky', or subject to protein degradation. The CNVs and SNVs affecting the transmembrane domain of GRIN1 may very well exert a phenotypic effect by producing completely inactive or 'leaky'NMDA receptors [Lemke et al., 2016] . If, on the other hand, the mutant allele of a gene would suppress the expression of the wild-type allele, as was the case in a patient with an intragenic deletion in the CNTNAP2 gene, significantly less than 50% of wild-type transcript would remain [Lee et al., 2015] . The latter may be the case with the in-frame deletion of CAPN3 [Vissing et al., 2016] . However plausible these explanations for dominant effects of mutations in transmembrane or dimerization domains of proteins may seem, they need corroboration by functional studies. The cell physiological investigations on Xenopus leavis oocytes may be complemented by proteomics and by, for instance, studies of inducible pluripotent stem cells from patients with mutations in these and other genes [Lemke et al., 2016] . The results of such studies may help to broaden our insights into the mechanisms of dominant action of certain mutations in genes that are otherwise known for recessive inheritance. In this way, the present studies not only 'blur the borders of dominant and recessive inheritance', but may also inspire a whole new realm of functional investigation.
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